CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS

Tracy L Mcgaha

The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDSC development

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Robert Zygmunt Orlowski

Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma

Multiple myeloma and immunoproliferative diseases

Jens G Lohr

Determining the mutational landscape of circulating multiple myeloma cells

Multiple myeloma and immunoproliferative diseases

Pathology

Kenneth C Anderson

Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Elad Ziv

Influence of germ line genetic variation on myeloma progression and survival

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Ping Xie

Molecular mechanisms of B cell malignant transformation

Multiple myeloma and immunoproliferative diseases

Jetze J Tepe

Characterization of Non-Competitive Proteasome Binding

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Catriona HM Jamieson

(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Ralph D Sanderson

Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies